Comparison of Corneal Safety and Intraocular Pressure–Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions

Kumagami, Takeshi; Wakiyama, Harumi; Kusano, Mao; Kajiyama, Ayano; Miura, Yoko; Uematsu, Masafumi; Yoneda, Ai; Kurihara, Junko; Suzuma, Kiyoshi; Kitaoka, Takashi

doi:10.1089/jop.2013.0132

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No statistically significant differences in IOP were found following treatment switch, which is consistent with previous studies demonstrating similar IOP lowering efficacies …”

Section: Discussionsupporting

confidence: 91%

“…Tafluprost 0.0015% is an ophthalmic solution in which BAC concentration is recently reduced. Additionally, reduced prevalence of superficial punctate keratopathy (SPK) has been shown in a clinical comparison of tafluprost to latanoprost . In this study, we evaluated changes in the ocular surface status and IOP lowering effects of patients with POAG or OH and the presence of existing prostaglandin‐induced corneal disorders after being switched from latanoprost 0.005% to tafluprost 0.0015% ophthalmic solution.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride

Wong

Aung

2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Importance Glaucoma treatment has often been associated with adverse side‐effects from preservatives that are included in the used eye drops. Background To evaluate changes in the ocular surface and the presence of prostaglandin‐induced corneal disorders after being switched from latanoprost 0.005% to low preservative tafluprost 0.0015% ophthalmic solution. Design Single centre, prospective study. Participants Patients with primary open‐angle glaucoma or ocular hypertension that had received treatment with once daily latanoprost 0.005% ophthalmic solution for control of intraocular pressure (IOP) for 3 months, with a score of above 1 on the National Eye Institute (NEI) ocular surface staining scale. Methods Following the ≥3 month latanoprost treatment period, patients were switched to once daily low preservative tafluprost 0.0015% ophthalmic solution. Patients were followed for a minimum of 3 months. Main Outcome Measures Ocular surface changes were assessed by fluorescein staining score (NEI scale). Additional evaluations included tear break‐up time, hyperaemia score, subjective symptoms, changes in intraocular pressure and presence of adverse reactions. Results Out of 59 patients enrolled, 51 were included in the final analysis. Fluorescein staining scores at baseline, prior to treatment switch, were 6.9 ± 3.1 and 3.3 ± 2.7 at the end of the study period (change in scores was −3.6 ± 2.2 [P < 0.001]). At last follow‐up, significant improvements were observed in tear break‐up time, hyperaemia score and subjective symptoms (all P < 0.05). Conclusions and Relevance The clinical signs of ocular surface disease and subjective symptoms of dry eyes improved following the switch to low preservative tafluprost and demonstrated comparable IOP lowering effectiveness.

show abstract

“…No statistically significant differences in IOP were found following treatment switch, which is consistent with previous studies demonstrating similar IOP lowering efficacies …”

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride

Wong

Aung

2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Data from in vitro studies using human corneal epithelial cells and in vivo studies using rabbit models have revealed that BAC is the major cause of keratoepithelial disorders 14. After switching from latanoprost to a tafluprost formulation containing lower levels of BAC or to a travoprost formulation containing SofZia instead of BAC, the prevalence of SPK was found to decrease in two clinical studies 10,15. In addition, topical β-blockers, which decrease corneal sensitivity16 and the number of goblet cells in the conjunctiva,17 have also been associated with an increased risk of keratoepithelial disorders 11.…”

Section: Discussionmentioning

confidence: 99%

“…Owing to the risk of toxic effects with long-term use, preservative-free or less toxic formulations of IOP-lowering agents have been developed to reduce the risk of OSDs. Treatment with tafluprost formulations containing 0.001% BAC has been shown to result in a lower prevalence of superficial punctate keratopathy (SPK) than treatment with standard latanoprost formulations containing 0.02% BAC (Xalatan ® , Pfizer Inc., New York, NY, USA) 10. In addition, certain active ingredients such as timolol might also encourage the development of corneal epithelial disorders 11.…”

Section: Introductionmentioning

confidence: 99%

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Okumichi

Kiuchi

Baba³

et al. 2017

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the ocular-surface safety of a 0.001% benzalkonium chloride-containing tafluprost/timolol fixed combination (TTFC) in patients with primary open-angle glaucoma (POAG) or ocular hypertension who have inadequate intraocular pressure (IOP) control with latanoprost monotherapy.MethodsThis study is a multicenter, prospective, single-arm, open-label clinical study. Patients with POAG or ocular hypertension who have inadequate IOP control with latanoprost monotherapy were considered eligible. After providing informed consent, patients continued latanoprost monotherapy for 12 weeks, followed by a switch to TTFC. We evaluated the extent of ocular-surface damage using superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), hyperemia score, IOP, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate at 0, 4, and 12 weeks after switching.ResultsA total of 68 patients were enrolled, of whom, 64 patients were included in the final analysis. No significant changes in SPK score, TBUT, or hyperemia score were observed at 4 and 12 weeks compared with week 0. IOP decreased significantly at 4 (13.9±2.5 mmHg) and 12 (14.1±2.5 mmHg) weeks, relative to week 0 (15.3±2.7 mmHg). No significant changes in either SBP or DBP were observed during the study, although patients’ mean heart rate decreased significantly after switching to TTFC. Adverse drug reactions to TTFC occurred in seven patients including two incidences of asthma and one of arrhythmia, and no events were serious.ConclusionThe ocular-surface safety of TTFC is not significantly different to that of latanoprost. Furthermore, switching from latanoprost to TTFC in patients with insufficient IOP control has additive IOP-lowering effects. TTFC is an effective approach for patients receiving latanoprost monotherapy who require more intensive IOP reduction.

show abstract

“…An investigation of epithelial permeability and autofluorescence of the cornea in patients with POAG or ocular hypertension (OH) demonstrated that removal of BAK from timolol resulted in an improvement of corneal epithelial barrier function and in a reduction of complaints [ 12 ]. On the other hand, it was reported in 75% of glaucoma patients that the superficial punctate keratopathy (SPK) scores improved by switching their glaucoma drugs (either latanoprost or travoprost) to BAK-reduced tafluprost [ 13 ]. Besides, switching therapy from BAK-preserved latanoprost to travoprost without BAK significantly reduced the frequency of SPK in POAG or OH patients [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience

Lin

Wei

Liu

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To investigate the efficacy and safety of switching to 0.0015% tafluprost ophthalmic solution with reduced benzalkonium chloride (BAK) on primary open-angle glaucoma (POAG) patients with corneal disorders under 0.005% latanoprost treatment. Material and Methods. This was a single-arm, open-label, switching study on adult POAG patients treated with latanoprost 0.005% for more than 3 months, with corneal disorders but no dry eye therapy. All patients were switched to tafluprost 0.0015% and followed up for 3 months. The primary outcome was the change in fluorescein staining score (National Eye Institute/Industry [NEI] score) at the end of the study. Secondary outcomes included changes in intraocular pressure (IOP), tear break-up time (TBUT), hyperemia score, and other ocular and nonocular adverse events. Results. Of the 20 patients initially enrolled, 17 patients, all with POAG, completed the study. At the end of the study, the mean NEI score significantly decreased by 1.8 ± 2.2 ( p < 0.01 ). No significant changes in IOP were observed (12.8 ± 4.6 mmHg at baseline vs. 12.3 ± 4.0 mmHg on visit 2; p = 0.470 ). TBUT increased by 1.2 ± 1.7 seconds ( p < 0.05 ). The proportions of patients with no sign of hyperemia on the bulbar and palpebral conjunctiva increased from 58.5% to 64.7% at baseline (before switching to tafluprost treatment) to 94.1% and 94.1%, respectively, after switching to tafluprost treatment. Dry eye sensation scores were significantly reduced ( p < 0.05 ), while other ocular symptom scores did not change significantly. Conclusion. Switching to tafluprost 0.0015% significantly improved fluorescein staining score, TBUT, and conjunctival hyperemia while maintaining IOP control among POAG patients with corneal disorders.

show abstract

Comparison of Corneal Safety and Intraocular Pressure–Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions

Cited by 8 publications

References 17 publications

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience

Contact Info

Product

Resources

About